Your browser doesn't support javascript.
Efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalized with COVID-19: A protocol for a pragmatic clinical trial.
Chen, Justin Z; Hoang, Holly L; Yaskina, Maryna; Kabbani, Dima; Doucette, Karen E; Smith, Stephanie W; Lau, Cecilia; Stewart, Jackson; Zurek, Karen; Schultz, Morgan; Cervera, Carlos.
  • Chen JZ; Division of Infectious Diseases, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.
  • Hoang HL; Division of Infectious Diseases, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.
  • Yaskina M; Women and Children's Health Research Institute, University of Alberta, Edmonton, Alberta, Canada.
  • Kabbani D; Division of Infectious Diseases, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.
  • Doucette KE; Division of Infectious Diseases, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.
  • Smith SW; Division of Infectious Diseases, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.
  • Lau C; Pharmacy Services, Alberta Health Services, Edmonton, Alberta, Canada.
  • Stewart J; Pharmacy Services, Alberta Health Services, Edmonton, Alberta, Canada.
  • Zurek K; Pharmacy Services, Covenant Health, Edmonton, Alberta, Canada.
  • Schultz M; Pharmacy Services, Covenant Health, Edmonton, Alberta, Canada.
  • Cervera C; Division of Infectious Diseases, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.
PLoS One ; 17(3): e0265493, 2022.
Artículo en Inglés | MEDLINE | ID: covidwho-1759955
ABSTRACT

BACKGROUND:

The use of broad-spectrum antibiotics is widespread in patients with COVID-19 despite a low prevalence of bacterial co-infection, raising concerns for the accelerated development of antimicrobial resistance. Antimicrobial stewardship (AMS) is vital but there are limited randomized clinical trial data supporting AMS interventions such as prospective audit and feedback (PAF). High quality data to demonstrate safety and efficacy of AMS PAF in hospitalized COVID-19 patients are needed. METHODS AND

DESIGN:

This is a prospective, multi-center, non-inferiority, pragmatic randomized clinical trial evaluating AMS PAF intervention plus standard of care (SOC) versus SOC alone. We include patients with microbiologically confirmed SARS-CoV-2 infection requiring hospital admission for severe COVID-19 pneumonia. Eligible ward beds and critical care unit beds will be randomized prior to study commencement at each participating site by computer-generated allocation sequence stratified by intensive care unit versus conventional ward in a 11 fashion. PAF intervention consists of real time review of antibacterial prescriptions and immediate written and verbal feedback to attending teams, performed by site-based AMS teams comprised of an AMS pharmacist and physician. The primary outcome is clinical status at post-admission day 15 measured using a 7-point ordinal scale. Patients will be followed for secondary outcomes out to 30 days. A total of 530 patients are needed to show a statistically significant non-inferiority, with 80% power and 2.5% one-sided alpha assuming standard deviation of 2 and the non-inferiority margin of 0.5.

DISCUSSION:

This study protocol presents a pragmatic clinical trial design with small unit cluster randomization for AMS intervention in hospitalized COVID-19 that will provide high-level evidence and may be adopted in other clinical situations. TRIAL REGISTRATION This study is being performed at the University of Alberta and is registered at ClinicalTrials.gov (NCT04896866) on May 17, 2021.
Asunto(s)

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Programas de Optimización del Uso de los Antimicrobianos / Tratamiento Farmacológico de COVID-19 / Antibacterianos Tipo de estudio: Estudio experimental / Estudio observacional / Estudio pronóstico / Ensayo controlado aleatorizado Límite: Humanos Idioma: Inglés Revista: PLoS One Asunto de la revista: Ciencia / Medicina Año: 2022 Tipo del documento: Artículo País de afiliación: Journal.pone.0265493

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Programas de Optimización del Uso de los Antimicrobianos / Tratamiento Farmacológico de COVID-19 / Antibacterianos Tipo de estudio: Estudio experimental / Estudio observacional / Estudio pronóstico / Ensayo controlado aleatorizado Límite: Humanos Idioma: Inglés Revista: PLoS One Asunto de la revista: Ciencia / Medicina Año: 2022 Tipo del documento: Artículo País de afiliación: Journal.pone.0265493